
    
      This will be a nonrandomized, nonblinded, prospective observational study to correlate the
      results obtained with the traditional measures of success of endovascular revascularization
      of peripheral arteries for the treatment of chronic limb ischemia; i.e., ABPI, PVR with
      oxyhemoglobin (OxyHb) and deoxyhemoglobin (DeoxyHb) measurements obtained with a new imaging
      device manufactured by HyperMed Inc (OxyVu) that uses hyperspectral technology.
    
  